There’s a story
worth understanding.
Science, tribal enterprise, healthcare infrastructure and the questions shaping the next generation of regenerative medicine.
A starting point
for your reporting.
Clear Health Pass Holdings, LLC acts as authorized Tribal Agent and program manager for the Tribal Biotechnology & Health Consortium. The company has in-market Rampart™ DL Matrix wound-care tissue, a shared documentation platform and planned peptide and healthspan programs.
A text brief with dated status and reporting distinctions. No third-party endorsements are implied.
Get the context.
Speak to the team.
Request an interview, source documents, product context or clarification of a company statement.
Prepare a media inquiry↗contact@clearhealthpass.com · (800) 266-7207
In market versus in development
Rampart™ DL Matrix and the measurement app are described as in market. Platform beta layers, the sensing pipeline and the unlaunched peptide pathways have different statuses.
Regulated versus approved
Rampart™ is an FDA-regulated Section 361 HCT/P. It is not FDA-approved or cleared.
Agency receipt versus endorsement
A record of correspondence or evidence receipt does not mean a federal agency endorses the company, agrees with its position or has granted coverage.
Tribal ownership versus company agency
Rampart™ is tribally owned through the Consortium, with CHP acting as agent and licensee under written delegations.
Story leads
All stories↗
Three pathways. One higher standard for peptides.
Inside the planned approach to clinical services, research and institutional supply.
Read the story↗
Clinical evidence enters the government-to-government record.
CHP reports CMS acknowledgment of its Rampart™ DL Matrix real-world evidence submission.
Read the story↗
The Q4347 company listing: “Tribal.”
The company’s account of a distinctive entry in the December 2025 CMS pricing schedule.
Read the story↗
HEAL WELL. AGE WELL. LIVE LONGER.